Casgevy in Kuwait

Casgevy - overview

Casgevy (exagamglogene autotemcel) is manufactured by Vertex/CRISPR and indicated for Sickle cell disease; transfusion-dependent beta-thalassemia. It is a Gene edit (CRISPR) approved by the US FDA in 2023 and may be accessible to patients in Kuwait through a Named Patient Program or personal-import pathway.

Access in Kuwait

Kuwait's Ministry of Health operates a Personal Import pathway for specialty drugs not registered locally, typically through a hospital pharmacy with physician attestation.

How Reserve Meds coordinates access in Kuwait

1. Patient or treating physician submits a request.
2. We verify clinical appropriateness and Kuwait-specific eligibility.
3. Treating physician in Kuwait issues prescription and clinical justification.
4. Country-specific NPP/personal-import forms are prepared and filed.
5. We source Casgevy from a DSCSA-compliant US specialty wholesaler.
6. Cold-chain shipment to the patient's physician or hospital pharmacy in Kuwait.

Typical timeline for Kuwait

End-to-end, most requests are completed in 2-6 weeks. Kuwait's tier 2 regulatory maturity typically supports moderate processing times.

What patients and physicians in Kuwait ask

• Is the pathway legal in Kuwait? Yes - it operates under Kuwait's established NPP or personal-import framework.
• Does my insurance cover it? Typically no for NPP drugs; patient prepayment is standard.
• What physician credentials do I need? A licensed physician in Kuwait able to issue the prescription and clinical justification.
• What if the drug is in shortage? We will inform you upfront and decline rather than promise what we cannot deliver.
• Can I re-supply? Yes - for chronic therapies we arrange ongoing re-supply.

Start a request for Casgevy in Kuwait

Request Casgevy